Bevacizumab to prevent haemorrhage after vitrectomy for proliferative diabetic retinopathy

Preoperative use of bevacizumab in diabetic vitrectomy may reduce the incidence of early postoperative vitreous cavity haemorrhage.

Comment: The quality of evidence is downgraded by limitations in study quality and by imprecise results (limited study size for each comparison).

Summary

A Cochrane review on perioperative use of anti-vascular endothelial growth factor (anti-VEGF) for prevention of postoperative vitreous cavity haemorrhage (POVCH) after vitrectomy for proliferative diabetic retinopathy included 4 studies with a total of 198 subjects (202 eyes). One of the included studies support the use of preoperative intravitreal bevacizumab to reduce the incidence of early POVCH. The remaining studies suggest that the preoperative use of bevacizumab may reduce the incidence of early POVCH, but significant methodological issues in these studies warrant cautiousness in interpreting their findings.

Clinical comments

Note

Date of latest search:

Ədəbiyyat

1. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2011;5:CD008214.